Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5368056 | 0.90 | CYP2C9 (0.35) | CYP2C9KMT2AALDH1A1GAALMNA | |
| SCHEMBL5370604 | 0.88 | CYP2C9 (0.35) | CYP2C9KMT2AALDH1A1GAA | |
| SCHEMBL5364325 | 0.86 | BRS3 (0.42) | CYP2C9KMT2AALDH1A1GAALMNA | |
| SCHEMBL5362262 | 0.84 | CYP2C9 (0.34) | CYP2C9KMT2AALDH1A1PAX8 | |
| SCHEMBL5368298 | 0.82 | CYP2C9 (0.34) | CYP2C9KMT2AALDH1A1PAX8 | |
| SCHEMBL5368635 | 0.81 | CYP2C9 (0.39) | CYP2C9KMT2AALDH1A1GAALMNA | |
| SCHEMBL5370608 | 0.80 | KMT2A (0.40) | KMT2AALDH1A1GAALMNAPAX8 | |
| SCHEMBL5763035 | 0.80 | CYP2C9 (0.39) | CYP2C9KMT2AALDH1A1GAA | |
| SCHEMBL5364335 | 0.80 | BRS3 (0.43) | CYP2C9KMT2AALDH1A1GAALMNA | |
| Lithium Ion SCHEMBL5367188 | 0.78 | CYP2C9 (0.38) | CYP2C9KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | CYP2C9 59/4885KMT2A 1672/4885ALDH1A1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.